Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded
NEWS 22	Jul 02	FOREGE no longer contains STANDARDS file segment

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of use privileges and other penalties

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:40:53 ON 11 JUL 2002

=> file medline, uspatful, dgene, embase, wpids, biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 15:41:11 ON 11 JUL 2002

FILE 'USPATFULL' ENTERED AT 15:41:11 ON 11 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:41:11 ON 11 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 15:41:11 ON 11 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:41:11 ON 11 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 15:41:11 ON 11 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s antimicrobial activity

L1 33283 ANTIMICROBIAL ACTIVITY

=> s l1 and polypeptide

L2 1000 L1 AND POLYPEPTIDE

=> s l2 and cysteine spacing

L3 1 L2 AND CYSTEINE SPACING

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 1 USPATFULL
TI Antimicrobial theta defensins and methods of using same
AB The present invention relates to an isolated cyclic peptide, theta defensin, having **antimicrobial activity**, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5 -Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence
Gly-Phe-Cys-Arg-Cys-Leu-Cys-Arg-
Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also relates to antibodies that specifically bind a theta defensin and to

isolated nucleic acid molecules encoding a theta defensin. In addition, the invention relates to methods of using theta defensin or a theta defensin analog to reduce or inhibit microbial growth or survival in an environment capable of sustaining microbial growth or survival by contacting the environment with the theta defensin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:1216 USPATFULL		
TITLE:	Antimicrobial theta defensins and methods of using same		
INVENTOR(S):	Selsted, Michael E., Irvine, CA, United States Tang, Yi-Quan, Irvine, CA, United States Yuan, Jun, Dove Canyon, CA, United States Ouellette, Andre J., Irvine, CA, United States		
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335318	B1	20020101
APPLICATION INFO.:	US 1999-309487		19990510 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Carlson, Karen Cochrane		
ASSISTANT EXAMINER:	Tu, Stephen		
LEGAL REPRESENTATIVE:	Campbell & Flores LLP		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 25 Drawing Page(s)		
LINE COUNT:	2067		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:40:53 ON 11 JUL 2002)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS' ENTERED AT 15:41:11 ON 11 JUL 2002

L1 33283 S ANTIMICROBIAL ACTIVITY
L2 1000 S L1 AND POLYPEPTIDE
L3 1 S L2 AND CYSTEINE SPACING

=> s l2 and cysteine

L4 306 L2 AND CYSTEINE

=> s l4 and spacing

L5 19 L4 AND SPACING

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 19 USPATFULL
TI Adenosine deaminase deficient transgenic mice and methods for the use thereof
AB The present invention relates to the production of adenosine deaminase (ADA) deficient mice and the use of such mice as an animal model for dysfunctions associated with elevated adenosine levels. Also, provided by the present invention are methods of treating dysfunctions associated
with elevated adenosine levels and methods of screening compounds for

pharmaceutical activity in the treatment of dysfunctions associated with
elevated adenosine levels.

ACCESSION NUMBER: 2002:166381 USPATFULL
TITLE: Adenosine deaminase deficient transgenic mice and methods for the use thereof
INVENTOR(S): Kellems, Rodney E., Houston, TX, UNITED STATES
Datta, Surjit K., Houston, TX, UNITED STATES
Blackburn, Michael R., Pearland, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002088017	A1	20020704
APPLICATION INFO.:	US 2001-761198	A1	20010116 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-301665, filed on 28 Apr 1999, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen M. Hash, Ph.D., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 7243

L5 ANSWER 2 OF 19 USPATFULL
TI Bacteriocins, transport and vector system and method of use thereof
AB New bacteriocins capable of inhibiting the growth of bacteria are disclosed, along with methods of obtaining secretion of proteins from lactic acid bacteria, and methods for protecting foodstuffs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:136557 USPATFULL
TITLE: Bacteriocins, transport and vector system and method of
use thereof
INVENTOR(S): Stiles, Michael E., 11623-33 Avenue, Edmonton, Alberta,
CANADA T6J 3G9
Vederas, John C., 9247 96 Street, Edmonton, Alberta, CANADA T6C 3Y5
Van Belkum, Marius J., De Vennen 12, 7921 HT Zuidwolde,
NETHERLANDS
Worobo, Randy W., Box 247, Consort, Alberta, CANADA
Worobo, Rodney J., Box 247, Consort, Alberta, CANADA T0C 1B0
McCormick, John K., 34 Evergreen Drive, Nepean, Ontario, CANADA K2H 6C8
Greer, G. Gordon, 5316 51 Avenue, Lacombe, Alberta, CANADA T4L 1J6
McMullen, Lynn M., 10528 75 Avenue, Edmonton, Alberta, CANADA T6E 1J4
Leisner, Jorgen J., 210, Blok 4, Pangsapuri, PKNS, Jalan 7/1 43300 Seri, Kembangan, Selangor D.E., MALAYSIA
Poon, Alison, 10908 40th Avenue, Edmonton, Alberta, CANADA T6J 0P8
Franz, Charles M. A. P., Hofacker Street 50, Karlfruhe 76139, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403082	B1	20020611
APPLICATION INFO.:	US 1997-924629		19970905 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-26257P	19960905 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mosher, Mary E.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 3114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 19 USPATFULL
TI Liquid detergent compositions comprising polymeric suds enhancers
AB The present invention relates to liquid detergent compositions comprising a polymeric material which is a suds enhancer and a suds volume extender, said compositions having increased effectiveness for preventing re-deposition of grease during hand washing. The polymeric material which are suitable as suds volume and suds endurance enhancers comprise an effective amount of a polymeric suds stabilizer comprise:

i) units capable of having a cationic charge at a pH of from about 4 to about 12;

provided that said suds stabilizer has an average cationic charge density from about 0.0005 to about 0.05 units per 100 daltons molecular weight at a pH of from about 4 to about 12.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:81454 USPATFULL
TITLE: Liquid detergent compositions comprising polymeric suds enhancers
INVENTOR(S): Kasturi, Chandrika, Cincinnati, OH, United States
Schafer, Michael Gayle, Alexandria, KY, United States
Sivik, Mark Robert, Mitchell, KY, United States
Kluesener, Bernard William, Harrison, OH, United States
Scheper, William Michael, Lawrenceburg, IN, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6372708	B1	20020416
APPLICATION INFO.:	US 2000-574524		20000518 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US24852, filed on 20 Nov 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-66747P	19971121 (60)
	US 1998-91672P	19980702 (60)
	US 1998-87714P	19980602 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hardee, John
LEGAL REPRESENTATIVE: Robinson, Ian S., Waugh, Kevin L., Cook, C. Brant

NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2079
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 19 USPATFULL
TI Novel matrix metalloproteinase (MMP-25) expressed in skin cells
AB This invention provides nucleic acids and polypeptides encoding a novel family of matrix metalloproteinases herein designated as MMP-25 and variants of the same. MMP-25 is preferentially expressed in skin cells of a mammal, particularly in breast cells and hair follicles. Expression in hair follicles is localized in the Henle layer of cells, indicating a role in hair growth. Also provided are fragments and oligonucleotides useful for identifying and isolating MMP-25-encoding nucleic acids and methods for their use, as well as antibodies that bind specifically to MMP-25 and vectors for expression of MMP-25 polypeptides. Methods of inhibiting MMP-25 activity are provided, including methods useful for inhibiting hair growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:67174 USPATFULL
TITLE: Novel matrix metalloproteinase (MMP-25) expressed in skin cells
INVENTOR(S): Wang, Kai, Bellevue, WA, UNITED STATES
Smith, Ryan, Seattle, WA, UNITED STATES
Fajardo, Mark, Shoreline, WA, UNITED STATES
Moss, Patrick, Shoreline, WA, UNITED STATES
Schatzman, Randall C., Shoreline, WA, UNITED STATES
LR

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002037827	A1	20020328	
APPLICATION INFO.:	US 2001-801196	A1	20010306	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-187196P	20000306 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 19 USPATFULL
TI Methods and reagents for isolating biologically active antibodies
AB One aspect of the present invention is the synthesis of a binary method that combines variegated antibody display libraries, e.g., in a "display mode", with soluble secreted antibody libraries, e.g., in a "secretion mode", to yield a method for the efficient isolation of antibodies having a desired biological activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:43170 USPATFULL
TITLE: Methods and reagents for isolating biologically active antibodies

INVENTOR(S): [redacted]yuris, Jeno, Winchester, MA, UN[redacted]ED STATES
[redacted]wert, Sebastian-Meier, Wolfrat[redacted]usen, GERMANY, FEDERAL REPUBLIC OF
Nagy, Zolton, Wolfratshausen, GERMANY, FEDERAL REPUBLIC
OF
Morris, Aaron, Brighton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025536	A1	20020228
APPLICATION INFO.:	US 2001-891557	A1	20010626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214200P	20000626 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
NUMBER OF CLAIMS: 83
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 19 USPATFULL
TI Use of multiple recombination sites with unique specificity in recombinational cloning
AB The present invention provides compositions and methods for recombinational cloning. The compositions include vectors having multiple recombination sites with unique specificity. The methods permit the simultaneous cloning of two or more different nucleic acid molecules. In some embodiments the molecules are fused together while in other embodiments the molecules are inserted into distinct sites in a vector. The invention also generally provides for linking or joining through recombination a number of molecules and/or compounds (e.g., chemical compounds, drugs, proteins or peptides, lipids, nucleic acids, carbohydrates, etc.) which may be the same or different. Such molecules and/or compounds or combinations of such molecules and/or compounds can also be bound through recombination to various structures or supports according to the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:12668 USPATFULL
TITLE: Use of multiple recombination sites with unique specificity in recombinational cloning
INVENTOR(S): Cheo, David, Kensington, MD, UNITED STATES
Brasch, Michael A., Gaithersburg, MD, UNITED STATES
Temple, Gary F., Washington Grove, MD, UNITED STATES
Hartley, James L., Frederick, MD, UNITED STATES
Byrd, Devon R. N., Montgomery Village, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002007051	A1	20020117
APPLICATION INFO.:	US 2000-732914	A1	20001211 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169983P	19991210 (60)

US 2000-188020P 20000309 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE. KESSLER, GOLDSTEIN & FOX P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC, 20005-3934
NUMBER OF CLAIMS: 142
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Page(s)
LINE COUNT: 9312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 19 USPATFULL
TI Antimicrobial theta defensins and methods of using same
AB The present invention relates to an isolated cyclic peptide, theta defensin, having **antimicrobial activity**, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5 -Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu-Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also relates to antibodies that specifically bind a theta defensin and to isolated nucleic acid molecules encoding a theta defensin. In addition, the invention relates to methods of using theta defensin or a theta defensin analog to reduce or inhibit microbial growth or survival in an environment capable of sustaining microbial growth or survival by contacting the environment with the theta defensin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:1216 USPATFULL
TITLE: Antimicrobial theta defensins and methods of using same
INVENTOR(S): Selsted, Michael E., Irvine, CA, United States
Tang, Yi-Quan, Irvine, CA, United States
Yuan, Jun, Dove Canyon, CA, United States
Ouellette, Andre J., Irvine, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335318	B1	20020101
APPLICATION INFO.:	US 1999-309487		19990510 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Tu, Stephen
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 25 Drawing Page(s)
LINE COUNT: 2067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 19 USPATFULL
TI Agouti **polypeptide** compositions
AB Disclosed are methods and compositions comprising novel agouti polypeptides and the polynucleotides which encode them. Also disclosed

are DNA segments encoding these proteins derived from human and murine cell lines, and the use of these polynucleotides and polypeptides in a variety of diagnostic and therapeutic applications. Methods, compositions, kits, and devices are also provided for identifying compounds which are inhibitors of agouti activity, and for altering fatty acid synthetase activity and intracellular calcium levels in transformed cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:191105 USPATFULL
TITLE:	Agouti **polypeptide** compositions
INVENTOR(S):	Woychik, Richard P., Orinda, CA, United States Bultman, Scott J., Lakewood, OH, United States Michaud, Edward J., Kingston, TN, United States
PATENT ASSIGNEE(S):	UT-Battelle, LLC, Oak Ridge, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6310034	B1	20011030
APPLICATION INFO.:	US 1998-34088		19980303 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-64385, filed on 21 May 1993, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Kammerer, Elyabik C.
LEGAL REPRESENTATIVE:	Williams, Morgan & Amerson
NUMBER OF CLAIMS:	34
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	83 Drawing Figure(s); 41 Drawing Page(s)
LINE COUNT:	10935

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 19 USPATFULL

TI Peptide antiestrogen compositions and methods for treating breast cancer

AB Disclosed are methods and compositions comprising native, site-specifically mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator, and nucleic acid compositions encoding these **polypeptide** compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers, the preparation of pharmaceutical compositions, diagnostic kits, and the development of related assays for use in antitumor therapies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:185267 USPATFULL
TITLE:	Peptide antiestrogen compositions and methods for treating breast cancer
INVENTOR(S):	Pietras, Richard J., Sherman Oaks, CA, United States
PATENT ASSIGNEE(S):	University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6306832	B1	20011023
APPLICATION INFO.:	US 1999-419826		19991014 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US7711, filed on 14 Apr 1998		

NUMBER	DATE

PRIORITY INFORMATION: US 1997-43545P 19970414 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fredman, Jeffrey
LEGAL REPRESENTATIVE: Howrey Simon Arnold & White, LLP
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 5797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 19 USPATFULL
TI Antimicrobial peptides from bovine neutrophis
AB The present invention provides a new family of **cysteine**-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:48022 USPATFULL
TITLE: Antimicrobial peptides from bovine neutrophis
INVENTOR(S): Selsted, Michael E., Irvine, CA, United States
Cullor, James S., Woodland, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211148	B1	20010403
APPLICATION INFO.:	US 1997-988705		19971211 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-356832, filed on 13 Dec 1994, now patented, Pat. No. US 5821224
Continuation of Ser. No. US 1993-33873, filed on 19 Mar 1993, now patented, Pat. No. US 5459235
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Bugaisky, Gabriele E.
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 30 Drawing Page(s)
LINE COUNT: 1360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 19 USPATFULL
TI Adenosine deaminase deficient transgenic mice and methods for the use thereof
AB The present invention relates to the production of adenosine deaminase (ADA) deficient mice and the use of such mice as an animal model for dysfunctions associated with elevated adenosine levels. Also, provided by the present invention are methods of treating dysfunctions associated with elevated adenosine levels and methods of screening compounds for pharmaceutical activity in the treatment of dysfunctions associated with elevated adenosine levels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:44433 USPATFULL
TITLE: Adenosine deaminase deficient transgenic mice and methods for the use thereof
INVENTOR(S): Kellems, Rodney E., Houston, TX, United States
Datta, Surjit K., Houston, TX, United States
Blackburn, Michael R., Pearland, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207876	B1	20010327
APPLICATION INFO.:	US 1999-301665		19990428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83408P	19980429 (60)
	US 1998-83370P	19980428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: LeGuyader, John L.
ASSISTANT EXAMINER: Kaushal, Sumesh
LEGAL REPRESENTATIVE: Fulbright Jaworski, LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 6595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 19 USPATFULL
TI Reaction vessel agitation apparatus
AB A device and method for efficiently synthesizing diverse molecular products on substrates. A parent vessel 200 contains a suspension of substrates. The suspension is pressurized with argon and transferred to a plurality of reaction vessels 201-209 in one or more reaction vessel banks where monomer addition reactions take place. Optionally, the substrates may be tagged with a tag monomer. A vortexing motor 300 vortexes the contents of reaction vessels 201-209 during monomer addition reactions to enhance synthesis. After the desired monomer and/or tag monomer addition reaction, the suspension is pressurized with argon and transferred back to parent vessel 200 for mixing. Thereafter, the suspension may be pressurized with argon and reallocated among reaction vessels 201-209 for further synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:174406 USPATFULL
TITLE: Reaction vessel agitation apparatus
INVENTOR(S): Kedar, Haim, Palo Alto, CA, United States
PATENT ASSIGNEE(S): Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6165778		20001226
APPLICATION INFO.:	US 1998-109613		19980702 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-432312, filed on 1 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-146886, filed on 2 Nov 1993, now patented, Pat. No. US 5639603 And a continuation-in-part of Ser. No. US 1993-149675, filed on 2 Nov 1993, now patented, Pat. No. US 5503805
DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Weisner, William H.
LEGAL REPRESENTATIVE: Gibby, Darin J., Murphy, Matthew B., Stevens, Lauren L.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 50 Drawing Page(s)
LINE COUNT: 6197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 19 USPATFULL
TI Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AB Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic **polypeptide**. Exemplary polypeptides disclosed include tissue plasminogen activator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:84056 USPATFULL
TITLE: Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
INVENTOR(S): Georgiou, George, Austin, TX, United States
Oiu, Ji, Austin, TX, United States
Bessette, Paul, Austin, TX, United States
Swartz, James, Menlo Park, CA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6083715		20000704	
APPLICATION INFO.:	US 1997-871483		19970609	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
ASSISTANT EXAMINER: Tung, Peter P.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 19 USPATFULL
TI Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
AB Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing **polypeptide** in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:21382 USPATFULL
TITLE: Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
INVENTOR(S): Georgiou, George, Austin, TX, United States
Ostermeier, Marc, State College, PA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6027888		20000222	
APPLICATION INFO.:	US 1997-834516		19970404	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14950P	19960405 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Guzo, David
ASSISTANT EXAMINER: Sandals, William
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 4029
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 19 USPATFULL
TI Natural resistance associated macrophage protein and uses thereof
AB A natural resistance-associated macrophage protein and corresponding promoter and antibodies specific thereto are provided. The promoter region exhibits polymorphisms and is useful as a diagnostic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:18918 USPATFULL
TITLE: Natural resistance associated macrophage protein and uses thereof
INVENTOR(S): Barton, Charles Howard, Southhampton, United Kingdom
White, Jacqueline Katie, Cambridge, MA, United States
Blackwell, Jenefer Mary, London, United Kingdom
PATENT ASSIGNEE(S): The Wellcome Trust Limited as Trustee to the Wellcome Trust, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5869247		19990209	
	WO 9520044		19950727	
APPLICATION INFO.:	US 1996-676279		19961008	(8)
	WO 1995-GB95		19950119	
			19961008	PCT 371 date
			19961008	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-929	19940119
	GB 1994-22021	19941031

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Shoemaker, Debra
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 19 USPATFULL
TI Antimicrobial peptides from bovine neutrophils
AB The present invention provides a new family of **cysteine**-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:124550 USPATFULL		
TITLE:	Antimicrobial peptides from bovine neutrophils		
INVENTOR(S):	Selsted, Michael E., Irvine, CA, United States Cullor, James S., Woodland, CA, United States		
PATENT ASSIGNEE(S):	Regents of the University of California, Alameda, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5821224		19981013
APPLICATION INFO.:	US 1994-356832		19941213 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-33873, filed on 19 Mar 1993, now patented, Pat. No. US 5459235		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Bugalsky, Gabriele E.		
LEGAL REPRESENTATIVE:	Campbell & Flores LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	49 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	1557		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 19 USPATFULL
TI Synthesizing and screening molecular diversity
AB A general stochastic method for synthesizing compounds can be used to generate large collections of tagged compounds that can be screened to identify and isolate compounds with useful properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:51857 USPATFULL		
TITLE:	Synthesizing and screening molecular diversity		
INVENTOR(S):	Dower, William J., Menlo Park, CA, United States Barrett, Ronald W., Sunnyvale, CA, United States Gallop, Mark A., Palo Alto, CA, United States Needels, Michael C., Oakland, CA, United States		
PATENT ASSIGNEE(S):	Affymax Technologies N.V., Curacao, Netherlands Antilles (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5639603		19970617
APPLICATION INFO.:	US 1993-146886		19931102 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-946239, filed on 16 Sep 1992 which is a continuation-in-part of Ser. No. US 1991-762522, filed on 18 Sep 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Ketter, James
LEGAL REPRESENTATIVE: Kaster, Kevin, Norviel, Vern, Stevens, Lauren L.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3125
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 19 USPATFULL
TI Reverse antimicrobial peptides
AB The present invention relates to several types of antimicrobial peptides
including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 96:43765 USPATFULL
TITLE: Reverse antimicrobial peptides
INVENTOR(S): Mapelli, Claudio, Princeton, NJ, United States
Swerdloff, Michael D., Princeton, NJ, United States
Williams, Jon I., Robbinsville, NJ, United States
Everett, Nicholas P., Pennington City, NJ, United States
PATENT ASSIGNEE(S): Enichem S.p.A., Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5519115		19960521
APPLICATION INFO.:	US 1993-164151		19931209 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-649784, filed on 1 Feb
1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
ASSISTANT EXAMINER: Huff, Sheela J.
LEGAL REPRESENTATIVE: Lerner, David, Littenberg, Krumholz & Mentlik
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 4886
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 19 USPATFULL
TI Antimicrobial peptides antibodies and nucleic acid molecules from bovine
neutrophils
AB The present invention provides a new family of **cysteine**-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and
veterinary medicine, and as agents in agricultural, food science, and industrial applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 95:92882 USPATFULL
TITLE: Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
INVENTOR(S): Selsted, Michael E., Irvine, CA, United States
Cullor, James S., Woodland, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5459235		19951017	
APPLICATION INFO.:	US 1993-33873		19930319	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lacey, David L.
ASSISTANT EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Campbell and Flores
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT: 1488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.